Effect of antiretrovirals on renal function in people taking HIV pre-exposure prophylaxis
Priscila Silva Pontes-Pereira, Rodrigo de Carvalho Santana, Elucir Gir, Renata Karina Reis, Priscila Silva Pontes-Pereira, Rodrigo de Carvalho Santana, Elucir Gir, Renata Karina Reis, Priscila Silva Pontes-Pereira, Rodrigo de Carvalho Santana, Elucir Gir, Renata Karina Reis

TL;DR
This study found that people taking HIV pre-exposure prophylaxis (PrEP) had low rates of kidney problems over 48 weeks.
Contribution
The study provides new evidence on the safety of antiretrovirals used in PrEP regarding renal function over a long-term period.
Findings
Low incidence of renal dysfunction markers like proteinuria and eGFR decline ≥25% in PrEP users over 48 weeks.
No significant association between eGFR decline and markers of renal damage.
Most participants showed mild and isolated kidney-related events with minimal variation over time.
Abstract
to evaluate the effect of antiretrovirals on renal function in individuals receiving HIV pre-exposure prophylaxis. a descriptive, longitudinal survey design was used in a retrospective cohort study for 48 weeks. The sample consisted of 203 participants. Non-probabilistic convenience sampling was used. Sociodemographic, clinical, and laboratory variables were analyzed. Absolute and relative frequencies, mean, standard deviation, minimum and maximum values, Fisher’s exact test, and Friedman test were used, with a significance level of <5%. the participants were predominantly cisgender men (86.2%), white (69.1%), highly educated (76.7%), and had a mean age of 34 years. The presence of markers of renal damage was low. Proteinuria increased until the 12th week (2.6%), maintaining a small variation until the 48th week. The decline in estimated Glomerular Filtration Rate (eGFR) ≥25% from…
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Click any figure to enlarge with its caption.
Figure 1
Figure 2
Figure 3Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsHIV/AIDS drug development and treatment · HIV-related health complications and treatments · HIV/AIDS Research and Interventions
